Handa Pharmaceuticals, Inc. was Pharmira Laboratories, Inc. To expand upon product research and development (R&D) capabilities, create plans for global marketing, and achieve the goals of international R&D and sales, Pharmira carried out cash acquisition of Handa Pharmaceuticals, LLC (Handa US) and its subsidiary Hangzhou Handa Pharmaceutical Technology Co., Ltd. (Hangzhou Handa) in February 2016. The original shareholders of Handa US then participated in capital increase of Pharmira, and after evaluating global and after reviewing global positioning and future business development, this Company, following approval, renamed itself to Handa Pharmaceuticals, Inc.
Handa US, a subsidiary of the Company, is also a pharmaceutical manufacturing R&D company, and specializes in developing controlled-release dosage forms and development of generic drugs with patent barriers (Paragraph IV). Since 2008, Handa US began submitting multiple abbreviated new drug applications (ANDA) for review to the US FDA and the Canadian competent authority for pharmaceutical administration. The applications include 2 successful cases of first-to-file (FTF) generic drugs, demonstrating the company’s extensive experiences in the Northern American market and commercialization.
The Company also has a second-tier subsidiary Hangzhou Handa through its subsidiary Handa US. The second-tier subsidiary is an important R&D center for the global positioning efforts of Handa, and owns large R&D areas in the city of Hangzhou. In addition to development capabilities of generic drugs with high barrier, the Hangzhou Handa can also support the Company in its plans for developing the pharmaceutical market in Mainland China.